Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Jay Backstrom; President, Chief Executive Officer, Director; Scholar Rock Holding Corp Tracey Sacco ... development of a apitegromab into other neuromuscular indications. We also continue to ...

Scholar Rock is gearing up for a potential commercial launch of its spinal muscular atrophy (SMA) treatment in the fourth quarter of 2025, with plans to expand its neuromuscular franchise and ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

And Scholar Rock continues to partner and learn from ... our reach to the youngest of those with SMA and to other rare neuromuscular disorders, we are on the threshold of establishing a ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions ...

Scholar Rock Holding Corporation (NASDAQ ... setting the stage for us to expand the development of apitegromab into other ...